Under a Nov. 16 deal, 2,466,395 Arcturus Therapeutics (ARCT) shares are issuable to Meiji Seika Pharma.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Meiji Seika Pharma Co., Ltd. has reported a 7.88% passive stake in Arcturus Therapeutics Holdings Inc. (ARCT), comprising 2,466,395 shares. This ownership percentage is based on 28,822,514 shares outstanding as of November 3, 2026, plus the shares issuable under a Securities Purchase Agreement dated November 16, 2026. Meiji Seika Pharma holds sole voting and dispositive power over these shares.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.